J&J gets FDA clearance for general surgery robot; study finds 90% of approved drugs meet post-marketing commitments

J&J received FDA authorization for a general‑surgery robot, a notable regulatory step for the company.

The FDA is also being urged to ban direct‑to‑consumer drug advertisements, highlighting ongoing policy discussions.

A JAMA Network Open study reported that nearly nine out of ten drugs approved by the FDA have completed their post‑marketing study requirements, with most results posted publicly on ClinicalTrials.gov or in other publications.

These developments underscore both the progress in medical device approvals and the importance of transparency in post‑approval drug monitoring.